These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 36450283)

  • 1. Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies.
    Bruel T; Stéfic K; Nguyen Y; Toniutti D; Staropoli I; Porrot F; Guivel-Benhassine F; Bolland WH; Planas D; Hadjadj J; Handala L; Planchais C; Prot M; Simon-Lorière E; André E; Baele G; Cuypers L; Mouthon L; Mouquet H; Buchrieser J; Sève A; Prazuck T; Maes P; Terrier B; Hocqueloux L; Schwartz O
    Cell Rep Med; 2022 Dec; 3(12):100850. PubMed ID: 36450283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies.
    Bruel T; Hadjadj J; Maes P; Planas D; Seve A; Staropoli I; Guivel-Benhassine F; Porrot F; Bolland WH; Nguyen Y; Casadevall M; Charre C; Péré H; Veyer D; Prot M; Baidaliuk A; Cuypers L; Planchais C; Mouquet H; Baele G; Mouthon L; Hocqueloux L; Simon-Loriere E; André E; Terrier B; Prazuck T; Schwartz O
    Nat Med; 2022 Jun; 28(6):1297-1302. PubMed ID: 35322239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum neutralization of SARS-CoV-2 Omicron BA.2, BA.2.75, BA.2.76, BA.5, BF.7, BQ.1.1 and XBB.1.5 in individuals receiving Evusheld.
    Zhao Q; Wang X; Zhang Z; Liu X; Wang P; Cao J; Liang Q; Qu J; Zhou M
    J Med Virol; 2023 Jul; 95(7):e28932. PubMed ID: 37403923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies.
    Planas D; Bruel T; Staropoli I; Guivel-Benhassine F; Porrot F; Maes P; Grzelak L; Prot M; Mougari S; Planchais C; Puech J; Saliba M; Sahraoui R; Fémy F; Morel N; Dufloo J; Sanjuán R; Mouquet H; André E; Hocqueloux L; Simon-Loriere E; Veyer D; Prazuck T; Péré H; Schwartz O
    Nat Commun; 2023 Feb; 14(1):824. PubMed ID: 36788246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants.
    Roe TL; Brady T; Schuko N; Nguyen A; Beloor J; Guest JD; Aksyuk AA; Tuffy KM; Zhang T; Streicher K; Kelly EJ; Kijak GH
    Microbiol Spectr; 2023 Mar; 11(2):e0033323. PubMed ID: 36877050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis.
    Tao K; Tzou PL; Kosakovsky Pond SL; Ioannidis JPA; Shafer RW
    Microbiol Spectr; 2022 Aug; 10(4):e0092622. PubMed ID: 35700134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies.
    Planas D; Bruel T; Staropoli I; Guivel-Benhassine F; Porrot F; Maes P; Grzelak L; Prot M; Mougari S; Planchais C; Puech J; Saliba M; Sahraoui R; Fémy F; Morel N; Dufloo J; Sanjuán R; Mouquet H; André E; Hocqueloux L; Simon-Loriere E; Veyer D; Prazuck T; Péré H; Schwartz O
    bioRxiv; 2022 Nov; ():. PubMed ID: 36415455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotypic and predicted phenotypic analysis of SARS-COV-2 Omicron subvariants in immunocompromised patients with COVID-19 following tixagevimab-cilgavimab prophylaxis.
    Ordaya EE; Vergidis P; Razonable RR; Yao JD; Beam E
    J Clin Virol; 2023 Mar; 160():105382. PubMed ID: 36731147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral activities of sotrovimab against BQ.1.1 and XBB.1.5 in sera of treated patients.
    Bruel T; Vrignaud LL; Porrot F; Staropoli I; Planas D; Guivel-Benhassine F; Puech J; Prot M; Munier S; Henry-Bolland W; Soulié C; Zafilaza K; Lusivika-Nzinga C; Meledge ML; Dorival C; Molino D; Péré H; Yordanov Y; Simon-Lorière E; Veyer D; Carrat F; Schwartz O; Marcelin AG; Martin-Blondel G;
    medRxiv; 2023 May; ():. PubMed ID: 37398037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies.
    Wilhelm A; Widera M; Grikscheit K; Toptan T; Schenk B; Pallas C; Metzler M; Kohmer N; Hoehl S; Marschalek R; Herrmann E; Helfritz FA; Wolf T; Goetsch U; Ciesek S
    EBioMedicine; 2022 Aug; 82():104158. PubMed ID: 35834885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.
    Hirsch C; Park YS; Piechotta V; Chai KL; Estcourt LJ; Monsef I; Salomon S; Wood EM; So-Osman C; McQuilten Z; Spinner CD; Malin JJ; Stegemann M; Skoetz N; Kreuzberger N
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD014945. PubMed ID: 35713300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2.
    Fiaschi L; Dragoni F; Schiaroli E; Bergna A; Rossetti B; Giammarino F; Biba C; Gidari A; Lai A; Nencioni C; Francisci D; Zazzi M; Vicenti I
    Viruses; 2022 Jun; 14(7):. PubMed ID: 35891355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and Treatment.
    Focosi D; Casadevall A
    Viruses; 2022 Sep; 14(9):. PubMed ID: 36146805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants.
    Brehm TT; Pfefferle S; von Possel R; Karolyi M; Zoufaly A; Wichmann D; Kobbe R; Emmerich P; Nörz D; Aepfelbacher M; Schulze Zur Wiesch J; Addo MM; Schmiedel S; Lütgehetmann M
    J Med Virol; 2022 Oct; 94(10):5038-5043. PubMed ID: 35662058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case.
    Tatham L; Kipar A; Sharp J; Kijak E; Herriott J; Neary M; Box H; Gallardo Toledo E; Valentijn A; Cox H; Pertinez H; Curley P; Arshad U; Rajoli RKR; Rannard S; Stewart JP; Owen A
    Microbiol Spectr; 2024 Aug; 12(8):e0391623. PubMed ID: 39012120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against Omicron subvariants BA.1, BA.2 and BA.5 and can be predicted by anti-S antibody concentrations in serological assays.
    Seidel A; Hoffmann S; Jahrsdörfer B; Körper S; Ludwig C; Vieweg C; Albers D; von Maltitz P; Müller R; Lotfi R; Wuchter P; Klüter H; Kirchhoff F; Schmidt M; Münch J; Schrezenmeier H
    Front Immunol; 2023; 14():1170759. PubMed ID: 37180152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineages.
    Touret F; Giraud E; Bourret J; Donati F; Tran-Rajau J; Chiaravalli J; Lemoine F; Agou F; Simon-Lorière E; van der Werf S; de Lamballerie X
    iScience; 2023 Apr; 26(4):106413. PubMed ID: 36968074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies to S2 domain of SARS-CoV-2 spike protein in Moderna mRNA vaccinated subjects sustain antibody-dependent NK cell-mediated cell cytotoxicity against Omicron BA.1.
    Balinsky CA; Jiang L; Jani V; Cheng Y; Zhang Z; Belinskaya T; Qiu Q; Long TK; Schilling MA; Jenkins SA; Corson KS; Martin NJ; Letizia AG; Hontz RD; Sun P
    Front Immunol; 2023; 14():1266829. PubMed ID: 38077368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75.
    Wang Q; Iketani S; Li Z; Guo Y; Yeh AY; Liu M; Yu J; Sheng Z; Huang Y; Liu L; Ho DD
    Cell Host Microbe; 2022 Nov; 30(11):1512-1517.e4. PubMed ID: 36108630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tixagevimab/Cilgavimab: Still a Valid Prophylaxis against COVID-19 New Variants?
    Gidari A; Sabbatini S; Bastianelli S; Pierucci S; Busti C; Svizzeretto E; Tommasi A; Pallotto C; Schiaroli E; Francisci D
    Viruses; 2024 Feb; 16(3):. PubMed ID: 38543720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.